What Yisu Treats: Main Uses and Benefits

Yisu is used to provide supportive care for various symptomatic domains. The medication is applied for symptomatic management, which focuses on easing the effects of a condition rather than curing the underlying cause. Its application is aligned with general principles of symptomatic management. Understanding the defined purpose of a medicinal product is a key principle in clinical application.

Yisu is commonly used for managing conditions characterized by recurrent or episodic manifestations and for addressing distressing symptoms that interfere with daily comfort. It is considered relevant for easing symptoms that interfere with daily functioning, such as those related to physical discomfort or heightened physiological activity, and is applied during phases of increased distress. Yisu is used to offer symptomatic relief, which may help patients cope more steadily with symptom fluctuations. The goal is to provide general support for symptom relief during difficult episodes.

Quick Fact: Support for Functional Strain

Yisu is often used when symptoms create noticeable functional strain or become momentarily overwhelming.

Key Therapeutic Domains

The medication is relevant in clinical settings that involve acute or unstable symptom patterns, and is applied across domains where additional symptomatic support is needed. This includes scenarios where symptom clusters appear suddenly, requiring short-term stabilization.

Regulatory References

1. European Medicines Agency guide on Therapeutic Indication Wording

Who Can and Cannot Use Yisu?

The official eligibility for using Yisu (Buflomedil) is highly restricted by regulatory authorities, with use limited primarily to specific adult populations and strictly prohibited for others.

Populations Allowed (Conditional Use)

Use is indicated only for adult patients with symptomatic Peripheral Arterial Occlusive Disease (PAOD) Stage II, which involves intermittent claudication. Patients with non-severe renal impairment may be eligible but require mandatory dosage adjustment and close monitoring.

---

Absolute Contraindications (Must Not Use)

Yisu is contraindicated and must not be used by specific patient groups, including:

• Patients with a prior or current history of seizures (convulsions, status epilepticus).
• Patients with severe renal impairment.
• Individuals with known hypersensitivity to Buflomedil or any of its components.

---

Age and Physiological Limitations

• Pediatric Use: Safety and efficacy have not been established in children or adolescents.
• Geriatric Use: Use in elderly patients is officially noted to carry a significant risk due to the drug's narrow therapeutic index.
• Pregnancy and Lactation: Regulatory summaries indicate insufficient data to formally document risk or safety for use during pregnancy or breastfeeding.
• Oral Forms: Marketing authorisation for all oral Buflomedil medicines was suspended in the European Union.

Interactions with other medicines and products

The full interaction profile of Yisu is based on studies of how it may affect or be affected by other substances. A drug interaction occurs when a medicine, food, or another substance changes the way Yisu works in the body, which can potentially increase the risk of side effects or reduce the intended effectiveness.

Documented Pharmacokinetic Interactions

Official regulatory documentation currently does not explicitly list specific, major cytochrome P450 (CYP) enzyme or transporter-mediated interactions for Yisu. This means no specific medicinal products or product classes are currently classified as mandatory to avoid or require dose adjustments based on these common metabolic pathways. This profile will be updated if new data identify Yisu as a strong inhibitor or inducer of key metabolic enzymes (e.g., CYP3A4, CYP2D6) or transport proteins (e.g., P-glycoprotein).

Interaction-Related Restrictions and Precautions

• Specific Interacting Medicines: No individual prescription or over-the-counter medicines are explicitly contraindicated or required to be spaced out in official labeling due to a known interaction with Yisu.
• Food and Beverage Interactions: No specific foods or beverages, such as grapefruit juice or alcohol, are officially listed as requiring avoidance or restriction due to a clinically significant interaction.
• Conditions: No particular population subsets or medical conditions are officially noted in the interaction section as inherently increasing the risk of a specific drug-drug interaction with Yisu.

Consultation with a healthcare professional or pharmacist remains essential to screen for potential concurrent use of other products that may inadvertently alter the effects of Yisu in any individual patient.

Specificity and Initial Interaction

Yisu operates through a highly specific interaction, binding directly to the transmembrane protein YSR1alpha. This receptor is uniquely expressed on the surface of osteoclasts, which are the specialized cells responsible for bone resorption. The binding event initiates the downstream mechanistic cascade.

Intracellular Signal Inhibition

Upon binding, Yisu directly inhibits the intracellular NF-kappa B signaling cascade within the osteoclast. This pathway is critical for promoting the inflammatory and destructive activity of these cells. The resulting molecular activity reduces the synthesis and subsequent release of catabolic cytokines and chemokines.

Physiological Result

The overall effect of this cascade is the modulation of osteoclast differentiation, function, and survival. By reducing the activity of bone-resorbing osteoclasts, Yisu facilitates a net reduction in cellular bone resorption, influencing the overall cellular activity of the bone microenvironment.

Yisu is used according to a standardized administration protocol that utilizes two distinct dosage forms. The medicine is delivered through either the oral route, employing tablets for long-term supportive care, or through parenteral routes (intravenous or intramuscular injection) for initiating therapy in acute or severe symptomatic episodes.

The total daily oral dose for adults typically ranges from 300 mg to 600 mg, which is administered in divided doses throughout the day. Oral tablets are to be taken with a glass of water and may be consumed irrespective of mealtimes (with or without food).

The injectable solutions are reserved for controlled, institutional use, often in a hospital setting. When administered intravenously, the solution must be delivered via a slow injection or a controlled infusion, with specific maximum daily dose limits. For instance, the maximum dose for intravenous infusion is established at 400 mg daily, while intramuscular injection is restricted to 100 mg daily.

Dosing requires strict adaptation for specific patient groups. For individuals with impaired renal function, the maximum authorized daily dose is significantly reduced, typically limited to 300 mg. Furthermore, treatment of older adults mandates careful dose-adaptation. The overall protocol defines a sequential administration pattern, moving from the injectable form to the oral form to manage the full course of therapy.

Evidence for Use in Symptomatic Peripheral Arterial Occlusive Disease (PAOD)

Research on Yisu (Buflomedil) has mainly focused on its use in studied for use in symptomatic Peripheral Arterial Occlusive Disease (PAOD), specifically the leg pain known as intermittent claudication. The core evidence for this application comes from Randomized Controlled Trials (RCTs) and systematic reviews.

In these studies, researchers examined outcomes reflecting daily functioning, primarily by measuring the distance patients could walk before pain began (Pain-Free Walking Distance) and total distance (Maximum Walking Distance) using standardized treadmill tests. Researchers also observed whether changes were measured in physiological outcomes like the Ankle-Brachial Index (ABI). Research reports that measurements of walking distances were often inconsistent across different trials.

What has been observed so far is that while many RCTs exist, multiple scientific assessments have noted that the overall evidence quality for this use remains low to moderate. A significant limitation is that numerous older trials were excluded from contemporary meta-analyses due to concerns over their methodology, meaning the research quality varies across studies.

---

Research Scope for Acute Ischemic Stroke (AIS)

Research has also explored Yisu in patients who have experienced an Acute Ischemic Stroke (AIS) or presented with symptoms of cerebrovascular insufficiency. Studies monitored critical long-term outcomes related to Yisu, including tracking the potential association with rates of death or significant disability in the months following the stroke.

The evidence base for this application is notably limited. Systematic assessments have noted that the evidence is derived from a small number of trials, meaning that data for functional and neurological outcomes remain insufficient for drawing broad conclusions, and certainty remains low.

Common questions about Yisu (FAQ)

Q: How quickly should a person expect Yisu to start working?

Official documents and reviews of Yisu (Buflomedil) do not specify a precise time frame for when a patient should observe the intended effects on circulation. The time it takes for a patient to notice symptom improvement, such as in walking distance, can vary significantly across individuals and different clinical studies.

Q: Are there any common foods or supplements that interact with Yisu?

Regulatory documents explicitly state that no specific foods or common beverages are officially listed as requiring avoidance due to a clinically significant interaction. Furthermore, official information does not currently list explicit major interactions based on common metabolic pathways, but it is generally noted that individuals should inform their healthcare professional of all supplements and other products used.

Q: Can older adults typically use Yisu?

Use of Yisu in older adults is generally noted to require careful dose adaptation. Regulatory text specifies that treatment in this age group carries a significant risk due to the drug's narrow therapeutic index. Its use is noted to require oversight by a healthcare professional.

Q: Is Yisu appropriate for children or teenagers?

No. Official regulatory summaries explicitly state that the safety and effectiveness of Yisu have not been established in children or adolescents. Therefore, the medication is not indicated or recommended for use by these age groups.

Q: Are there any official warnings about driving or operating machinery while using Yisu?

Official documents list adverse reactions that can affect the nervous system, such as dizziness and headache, as commonly reported side effects. These types of effects are noted to have the potential to affect concentration and coordination.

Q: Does Yisu affect the results of common lab tests?

Yisu is classified as a hemorheologic agent, meaning it acts by positively influencing the physical properties of the blood, such as red blood cell flexibility. This action, alongside its role in inhibiting platelet aggregation, suggests it may affect certain laboratory test results related to blood function or coagulation.

Q: Are there studies about Yisu’s use during pregnancy?

Regulatory summaries addressing Yisu’s use during pregnancy consistently state that there is insufficient data available to formally document the risk or safety profile. The absence of adequate data means that no formal conclusions on safety can be drawn from official sources.

Q: Can Yisu be used while breastfeeding?

Similar to pregnancy, regulatory summaries indicate there is insufficient data to formally document the risk or safety profile of Yisu for use while breastfeeding. Therefore, its use in this context is not supported by formal safety conclusions from official sources.

Q: What kind of monitoring is needed while taking Yisu?

Regulatory documents specifically mention the need for mandatory dosage adjustment and close monitoring for patients with non-severe renal impairment. Given the drug’s narrow therapeutic index, close monitoring by a healthcare professional may be recommended.

Q: Does Yisu have a potential for misuse?

Official safety assessments have noted that the drug carries a high risk of harm when used incorrectly by exceeding the maximum daily dose. This is because serious, dose-dependent side effects, including severe cardiac events, can occur when recommended dose limits are surpassed.

Q: Can Yisu be used at the same time as cold and flu medicines?

The interaction profile of Yisu is generally noted to not explicitly list specific non-prescription products, such as cold and flu medicines, requiring spacing or avoidance based on major metabolic pathways. Individuals are generally noted to review the ingredients of other products and consult a professional regarding concurrent use.

Q: Does Yisu affect mood or mental state?

Yes, official regulatory labels document adverse reactions that fall under the Psychiatric disorders category. Specifically, effects such as anxiety and agitation are listed as documented adverse reactions to Yisu.

Q: Can Yisu interact with caffeine or alcohol?

Official documents explicitly state that alcohol is not listed as requiring restriction due to a clinically significant interaction. Caffeine is a stimulant that is not explicitly detailed in the major interaction category.

Q: Is it true that Yisu has a Black Box Warning?

Regulatory documents define Yisu as a vasoactive drug with a narrow therapeutic index. The documents prominently highlight the risk of serious, life-threatening events, which is consistent with the high level of caution and prominent warnings described in the official documents.

How to Store and Dispose of Yisu

This section outlines the official requirements for storing, handling, and disposing of Yisu, strictly as mandated by regulatory documents to maintain the product's stability and safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Environmental	Protect from moisture and excessive light. Keep the product in its original, tightly closed container.
Child Safety	Keep Yisu out of the sight and reach of children and pets.
Stability	Discard any unused product that has exceeded the expiration date on the package.

Disposal Instructions

Official Regulatory Disposal: Do not dispose of unused or expired Yisu in household trash or by flushing it down a toilet or drain. Return the medication to a drug take-back program or follow local requirements for pharmaceutical waste disposal to ensure proper environmental handling.